Ofatumumab: A novel treatment for severe systemic lupus erythematosus

Rheumatology (United Kingdom)

Volumn 54, Issue 3, 2015, Pages 559-560

  Thornton, C Clare ^a   Ambrose, Nicola ^a   Ioannou, Yiannis ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; OFATUMUMAB; PREDNISOLONE; RITUXIMAB; SM ANTIBODY; STEROID;

ADULT; ANTIBODY TITER; ARTHRITIS; B LYMPHOCYTE; CASE REPORT; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; FEVER; HUMAN; HYPOCOMPLEMENTEMIA; LETTER; LYMPHOCYTE DEPLETION; MACROPHAGE ACTIVATION SYNDROME; PANCREATITIS; PERICARDITIS; PRIORITY JOURNAL; PROTEINURIA; RASH; RECURRENT FEVER; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN; WEIGHT REDUCTION; YOUNG ADULT;

EID: 84941660589     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu475     Document Type: Letter

References (5)

1. Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26.
2. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, doubleblind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
3. Condon MB, Ashby D, Pepper RJ et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-6.
4. Mysler EF, Spindler AJ, Guzman R et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 2013;65:2368-79.
5. Taylor PC, Quattrocchi E, Mallett S et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biologicalnaive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2011;70: 2119-25.